Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 18, 2026, 8:40 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 842 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Attention Deficit and Disruptive Behavior Disorders Clear all
Not listed No phase listed Observational

Screening Protocol for Adults With ADHD

NCT00592254
View directory record Official record
Conditions
ADHD
Interventions
Not listed
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years to 55 Years
Enrollment
3,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2023
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jan 17, 2022 · Synced Sep 18, 2026, 8:40 PM EDT
Completed Phase 1 Interventional

Task-Based Grounding Program

NCT04648553
View directory record Official record
Conditions
Aggressive, Defiant Disorder, Oppositional, Attention Deficit Hyperactivity Disorder
Interventions
Task-Based Grounding, Connected Care (Enhanced Treatment as usual)
Behavioral
Lead sponsor
Dartmouth-Hitchcock Medical Center
Other
Eligibility
9 Years and older
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
1
States / cities
Lebanon, New Hampshire
Source: ClinicalTrials.gov public record
Updated Nov 7, 2021 · Synced Sep 18, 2026, 8:40 PM EDT
Completed Phase 3 Interventional Results available

Phase 3 Efficacy and Safety Fixed-Dose Study in Pediatrics (6-17) With ADHD Using CTx-1301

NCT05286762
View directory record Official record
Conditions
ADHD, Attention Deficit Hyperactivity Disorder, ADHD - Combined Type, Attention Deficit Hyperactivity Disorder Combined, Attention-deficit Hyperactivity, Attention Deficit Hyper Activity
Interventions
CTx-1301-Dexmethylphenidate 12.5 mg (titration only), CTx-1301-Dexmethylphenidate 18.75mg (randomized fixed dose), CTx-1301-Dexmethylphenidate 25mg (randomized fixed dose), CTx-1301-Dexmethylphenidate 37.5 mg (randomized fixed dose), Placebo
Drug
Lead sponsor
Cingulate Therapeutics
Industry
Eligibility
6 Years to 17 Years
Enrollment
103 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
24
States / cities
Jacksonville, Florida • Maitland, Florida • Orlando, Florida + 21 more
Source: ClinicalTrials.gov public record
Updated Jan 21, 2026 · Synced Sep 18, 2026, 8:40 PM EDT
Completed Not applicable Interventional

Child and Family Outcomes and Consumer Satisfaction for Online vs Staff-Delivered Parenting Intervention

NCT02121431
View directory record Official record
Conditions
Childhood Disruptive Behavior Disorders, Oppositional Defiant Disorder, Conduct Disorder, Attention Deficit Hyperactivity Disorder, Parent-Child Interactions
Interventions
Triple P--Positive Parenting Program
Behavioral
Lead sponsor
University of South Carolina
Other
Eligibility
3 Years to 7 Years
Enrollment
334 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2019
U.S. locations
2
States / cities
Eugene, Oregon • Columbia, South Carolina
Source: ClinicalTrials.gov public record
Updated Apr 17, 2019 · Synced Sep 18, 2026, 8:40 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Sleep Dysfunction and Neurocognitive Outcomes in Adolescent ADHD

NCT02897362
View directory record Official record
Conditions
Attention Deficit Hyperactivity Disorder
Interventions
Not listed
Lead sponsor
Duke University
Other
Eligibility
13 Years to 17 Years
Enrollment
62 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2021
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Jul 13, 2021 · Synced Sep 18, 2026, 8:40 PM EDT
Recruiting Phase 4 Interventional Accepts healthy volunteers

Atomoxetine and Executive Function in PTSD

NCT06573970
View directory record Official record
Conditions
Posttraumatic Stress Disorder With Attention Defic
Interventions
Atomoxetine, Placebo
Drug
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
18 Years to 75 Years
Enrollment
160 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2029
U.S. locations
1
States / cities
Charleston, South Carolina
Source: ClinicalTrials.gov public record
Updated Jul 6, 2026 · Synced Sep 18, 2026, 8:40 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Comparative Effectiveness Research for Two Medical Home Models for Attention Deficit Hyperactivity Disorder

NCT01275378
View directory record Official record
Conditions
Attention Deficit/Hyperactivity Disorder
Interventions
Collaborative Care Plus, Traditional Collaborative Care
Behavioral
Lead sponsor
Boston Medical Center
Other
Eligibility
6 Years to 12 Years
Enrollment
156 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2014
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Oct 9, 2016 · Synced Sep 18, 2026, 8:40 PM EDT
Not listed Phase 1Phase 2 Interventional

Intervening Early With Neglected Children

NCT02093052
View directory record Official record
Conditions
Conduct Disorder, ADHD, Depression
Interventions
Attachment and Biobehavioral Catch-up, Developmental Education for Families
Behavioral
Lead sponsor
University of Delaware
Other
Eligibility
6 Years to 8 Years
Enrollment
220 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2024
U.S. locations
1
States / cities
Newark, Delaware
Source: ClinicalTrials.gov public record
Updated Nov 16, 2020 · Synced Sep 18, 2026, 8:40 PM EDT
Completed Phase 4 Interventional Results available

Efficacy and Safety of Dex-Methylphenidate Extended Release 30 mg Versus 20 mg in Children (6-12 Years) With Attention-Deficit/Hyperactivity Disorder (ADHD) in a Laboratory Classroom Setting.

NCT00776009
View directory record Official record
Conditions
Attention-Deficit/Hyperactivity Disorder (ADHD)
Interventions
Dex-Methylphenidate hydrochloride Extended Release (Focalin® XR), Placebo
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
6 Years to 12 Years
Enrollment
165 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008
U.S. locations
8
States / cities
Little Rock, Arkansas • Bradenton, Florida • South Miami, Florida + 4 more
Source: ClinicalTrials.gov public record
Updated Jun 7, 2011 · Synced Sep 18, 2026, 8:40 PM EDT
Completed Phase 3 Interventional Results available

Time Course of Response to Methylphenidate HCl ER Capsules in Children 6 to 12 Years With ADHD in Classroom Setting

NCT01269463
View directory record Official record
Conditions
Attention Deficit Hyperactivity Disorder, ADHD
Interventions
Methylphenidate Hydrochloride Extended Release Capsule, Placebo
Drug
Lead sponsor
Rhodes Pharmaceuticals, L.P.
Industry
Eligibility
6 Years to 12 Years
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
1
States / cities
Irvine, California
Source: ClinicalTrials.gov public record
Updated Dec 12, 2022 · Synced Sep 18, 2026, 8:40 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Study of Cognition and Control in Youths

NCT03393390
View directory record Official record
Conditions
Attention Deficit Hyperactivity Disorder, Oppositional Defiant Disorder, Conduct Disorder
Interventions
Clinical Assessment Visit, fMRI scan
Diagnostic Test · Other
Lead sponsor
University of Michigan
Other
Eligibility
6 Years to 18 Years
Enrollment
256 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2019
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Apr 13, 2022 · Synced Sep 18, 2026, 8:40 PM EDT
Active, not recruiting Not applicable Interventional

Interventions for English Language Learners At-Risk for ADHD

NCT05918991
View directory record Official record
Conditions
Attention Deficit Hyperactivity Disorder
Interventions
Daily Report Card, Language Intervention
Behavioral · Other
Lead sponsor
Florida International University
Other
Eligibility
Not listed
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Aug 19, 2026 · Synced Sep 18, 2026, 8:40 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Multidimensional Measurement of Psychopharmacological Treatment Response

NCT01184235
View directory record Official record
Conditions
Autism Spectrum Disorders, Mood Disorders, Sleep Disorders, Attention Deficit Disorders
Interventions
Pharmacological Intervention
Drug
Lead sponsor
Child Psychopharmacology Institute
Other
Eligibility
6 Months and older
Enrollment
44 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2011
U.S. locations
1
States / cities
Fargo, North Dakota
Source: ClinicalTrials.gov public record
Updated Jan 5, 2014 · Synced Sep 18, 2026, 8:40 PM EDT
Completed Phase 3 Interventional Results available

A Trial Evaluating the Long-term Safety and Tolerability of Centanafadine Sustained-release Tablets in Adults With Attention-Deficit/Hyperactivity Disorder

NCT03605849
View directory record Official record
Conditions
Attention Deficit Disorder, Attention Deficit Hyperactivity Disorder
Interventions
Centanafadine SR
Drug
Lead sponsor
Otsuka Pharmaceutical Development & Commercialization, Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
662 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
1
States / cities
Culver City, California
Source: ClinicalTrials.gov public record
Updated Sep 30, 2024 · Synced Sep 18, 2026, 8:40 PM EDT
Completed Phase 4 Interventional Results available

Examining Tolerance to CNS Stimulants in ADHD

NCT02039908
View directory record Official record
Conditions
Attention-deficit/Hyperactivity Disorder
Interventions
Methylphenidate
Drug
Lead sponsor
Florida International University
Other
Eligibility
6 Years to 12 Years
Enrollment
267 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2020
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Jun 8, 2020 · Synced Sep 18, 2026, 8:40 PM EDT
Completed Phase 3 Interventional Results available

Safety and Efficacy Study of SHP465 in Children and Adolescents Aged 6-17 Years With Attention-Deficit Hyperactivity Disorder (ADHD)

NCT02466425
View directory record Official record
Conditions
Attention Deficit Hyperactivity Disorder (ADHD)
Interventions
SHP465, Placebo
Drug
Lead sponsor
Shire
Industry
Eligibility
6 Years to 17 Years
Enrollment
264 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
36
States / cities
Dothan, Alabama • Orange, California • San Diego, California + 31 more
Source: ClinicalTrials.gov public record
Updated Jun 2, 2021 · Synced Sep 18, 2026, 8:40 PM EDT
Completed Phase 1 Interventional

Phase I Single Dose, Open-Label Pharmacokinetic Study and Single-Blind, Placebo-Controlled Dose Escalation Study of NFC-1 in Adolescents With Attention-Deficit Hyperactivity Disorder

NCT02286817
View directory record Official record
Conditions
Attention-deficit Hyperactivity Disorder (ADHD)
Interventions
NFC-1
Drug
Lead sponsor
Aevi Genomic Medicine, LLC, a Cerecor company
Industry
Eligibility
12 Years to 17 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Oct 20, 2025 · Synced Sep 18, 2026, 8:40 PM EDT
Completed Phase 4 Interventional Results available

A Safety/Tolerability and PK Study With Azstarys® in Children With ADHD

NCT05721235
View directory record Official record
Conditions
Attention Deficit/Hyperactivity Disorder
Interventions
Serdexmethylphenidate (SDX) and dexmethylphenidate (d-MPH)
Drug
Lead sponsor
Corium, Inc.
Industry
Eligibility
4 Years to 5 Years
Enrollment
123 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
20
States / cities
Little Rock, Arkansas • Anaheim, California • Centennial, Colorado + 17 more
Source: ClinicalTrials.gov public record
Updated May 7, 2026 · Synced Sep 18, 2026, 8:40 PM EDT
Completed Not applicable Interventional Results available

Investigation of Strategies to Reduce the Impact of the Relative Age Effect in Kindergarten

NCT05142826
View directory record Official record
Conditions
Attention Deficit Hyperactivity Disorder
Interventions
Relative Age Effect Intervention, School as Usual
Behavioral · Other
Lead sponsor
Florida International University
Other
Eligibility
4 Years to 5 Years
Enrollment
62 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
1
States / cities
Amherst, New York
Source: ClinicalTrials.gov public record
Updated Nov 18, 2025 · Synced Sep 18, 2026, 8:40 PM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

Executive Function Training for Children and Adolescents

NCT07147894
View directory record Official record
Conditions
Cognitive Change
Interventions
Nongamified N-back training, Gamified N-back training, Multiple Domain Training, Coaching Session
Behavioral
Lead sponsor
Northeastern University
Other
Eligibility
12 Years to 17 Years
Enrollment
780 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2028
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Dec 22, 2025 · Synced Sep 18, 2026, 8:40 PM EDT
Completed Not applicable Interventional Results available

Improving the Outcomes of Adolescents With ADHD Via a Pre-visit Question Prompt List/Video Intervention

NCT05835362
View directory record Official record
Conditions
ADHD
Interventions
Question Prompt List, Video Only
Behavioral
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
11 Years to 17 Years
Enrollment
252 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Jul 1, 2026 · Synced Sep 18, 2026, 8:40 PM EDT
Completed Phase 2 Interventional Results available

Study of the Safety and Efficacy of OPC-34712 as a Complementary Therapy in the Treatment of Adult Attention Deficit/Hyperactivity Disorder

NCT01074294
View directory record Official record
Conditions
Attention Deficit Hyperactivity Disorder
Interventions
OPDC-34712, Placebo, Stimulant Therapy
Drug
Lead sponsor
Otsuka Pharmaceutical Development & Commercialization, Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
740 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
35
States / cities
Little Rock, Arkansas • Beverly Hills, California • Irvine, California + 32 more
Source: ClinicalTrials.gov public record
Updated Feb 1, 2023 · Synced Sep 18, 2026, 8:40 PM EDT
Completed No phase listed Observational

Acceptability, Feasibility, and Development of an AI Driven, Multi-sensor, Non-invasive Digital Mental Health Platform in Children With ADHD and Emotional Symptoms

NCT06311370
View directory record Official record
Conditions
ADHD, Autism
Interventions
Observation
Other
Lead sponsor
MaxisHealth
Industry
Eligibility
4 Years to 7 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
1
States / cities
Brooklyn, New York
Source: ClinicalTrials.gov public record
Updated Mar 14, 2024 · Synced Sep 18, 2026, 8:40 PM EDT
Completed Phase 4 Interventional

Evaluation of Continuous Symptom Treatment of ADHD

NCT00486122
View directory record Official record
Conditions
Attention Deficit Hyperactivity Disorder
Interventions
Atomoxetine Hydrochloride, Placebo
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
6 Years to 12 Years
Enrollment
282 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2004
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Jun 12, 2007 · Synced Sep 18, 2026, 8:40 PM EDT